ClinicalTrials.Veeva

Menu

A Pilot Clinical Trial With Tocotrienol on Breast Cancer (BC)

M

Malaysia Palm Oil Board

Status

Completed

Conditions

Breast Cancer

Treatments

Other: placebo plus tamoxifen
Dietary Supplement: Tocotrienol Rich Fraction (TRF)

Study type

Interventional

Funder types

Other

Identifiers

NCT01157026
5399 S1 (Registry Identifier)
CT369

Details and patient eligibility

About

Tocotrienol Rich Fraction (TRF) in combination with Tamoxifen will improve breast cancer specific survival and recurrence free survival, in women with early breast cancer and estrogen receptor positive tumors.

Full description

We conducted a, double-blinded, placebo controlled trial of TRF plus tamoxifen versus placebo plus tamoxifen in women with primary breast cancer for five years. Both the TRF and placebo drugs were prepared and supplied by Hovid Sdn Bhd, Malaysia. Hovid Sdn. Bhd. absolutely did not have any influence in the trial designing, patient recruitment, data collection, analysis and reporting. The placebo drug which contained soy oil without tocotrienols had similar appearance and taste as the TRF drug. A total of 240 women breast cancer patients were assigned to two groups by minimization method that balanced treatment groups. The intervention group was given TRF plus tamoxifen, (n = 120) while control group was given placebo plus tamoxifen, (n = 120). The primary end point was breast cancer specific survival, defined as the time from minimization to death due to breast cancer. The secondary end points included disease free survival, biochemical parameters, liver function and plasma levels of vitamin E.

Enrollment

240 patients

Sex

Female

Ages

40 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. women with estrogen receptor positive tumors.
  2. 40-60 years of age at the start of the tamoxifen therapy.
  3. histologically confirmed primary breast cancer.
  4. a tumor that was positive for estrogen receptors, progesterone receptors, or both.
  5. an Eastern Cooperative Oncology Group performance status of 0,1, or 2 (scored on a scale of 0 to 5, with lower scores indicating better function).

Exclusion criteria

  1. concurrent use of investigational drugs and estrogen receptor status negative or unknown.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

240 participants in 2 patient groups

Tocotrienol Rich Fraction plus Tamoxifen
Experimental group
Treatment:
Dietary Supplement: Tocotrienol Rich Fraction (TRF)
Placebo plus tamoxifen
Active Comparator group
Treatment:
Other: placebo plus tamoxifen

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems